MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients

Degradation of extracellular matrix components is central to many pathological features of chronic destructive lung disorders. Desmosine and isodesmosine are elastin-derived cross-linked amino acids whose urine levels are considered representative of elastin breakdown. The aim of this study was to apply a novel methodology, based on high-performance capillary electrophoresis, to the quantification of desmosine and isodesmosine in 11 patients with stable chronic obstructive pulmonary disease (COPD), 10 with an exacerbation of COPD, nine with alpha1-antitrypsin deficiency, 13 with bronchiectasis, and 11 adults with cystic fibrosis, in comparison to 24 controls. It was found that, in patients with stable COPD, urinary desmosine levels were higher than in controls (p=0.03), but lower than in COPD subjects with an exacerbation (p< or =0.05). The highest desmosine levels were found in subjects with alpha1-antitrypsin deficiency, bronchiectasis and cystic fibrosis (p<0.001 versus stable COPD). In a short-term longitudinal study, five stable COPD patients showed a constant rate of desmosine excretion (mean coefficient of variation <8% over three consecutive days). In conclusion, the present method is simple and suitable for the determination of elastin-derived cross-linked amino acid excretion in urine, giving results similar to those obtained using other separation methods. In addition, evidence is presented that urinary desmosine excretion is increased in conditions characterized by airway inflammation, such as exacerbations of chronic obstructive pulmonary disease, bronchiectasis and cystic fibrosis. Results obtained in subjects with alphal-antitrypsin deficiency suggest that this method might be used to evaluate the putative efficacy of replacement therapy.

This article has been cited by other articles:

				M. Luisetti, S. Ma, P. Iadarola, P. J. Stone, S. Viglio, B. Casado, Y. Y. Lin, G. L. Snider, and G. M. Turino Desmosine as a biomarker of elastin degradation in COPD: current status and future directions Eur. Respir. J., November 1, 2008; 32(5): 1146 - 1157. [Abstract] [Full Text] [PDF]

				M. Miravitlles Review: Do we need new antibiotics for treating exacerbations of COPD? Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 61 - 76. [Abstract] [PDF]

				A. Anzueto, S. Sethi, and F. J. Martinez Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 554 - 564. [Abstract] [Full Text] [PDF]

				S. Ma, Y. Y. Lin, and G. M. Turino Measurements of Desmosine and Isodesmosine by Mass Spectrometry in COPD Chest, May 1, 2007; 131(5): 1363 - 1371. [Abstract] [Full Text] [PDF]

				P Boschetto, S Quintavalle, E Zeni, S Leprotti, A Potena, L Ballerin, A Papi, G Palladini, M Luisetti, L Annovazzi, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease Thorax, December 1, 2006; 61(12): 1037 - 1042. [Abstract] [Full Text] [PDF]

				E Sapey and R A Stockley COPD exacerbations {middle dot} 2: Aetiology. Thorax, March 1, 2006; 61(3): 250 - 258. [Abstract] [Full Text] [PDF]

				S. Ma, S. Lieberman, G. M. Turino, and Y. Y. Lin The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum PNAS, October 28, 2003; 100(22): 12941 - 12943. [Abstract] [Full Text] [PDF]

				M. Miravitlles Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur. Respir. J., July 1, 2002; 20(36_suppl): 9S - 19s. [Abstract] [Full Text] [PDF]

				M. G. Cosio, J. Majo, and M. G. Cosio Inflammation of the Airways and Lung Parenchyma in COPD* : Role of T Cells Chest, May 1, 2002; 121(5_suppl): 160S - 165S. [Abstract] [Full Text] [PDF]

				T. L. CROXTON, G. G. WEINMANN, R. M. SENIOR, and J. R. HOIDAL Future Research Directions in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 15, 2002; 165(6): 838 - 844. [Full Text] [PDF]